Terms: = Kidney tumors AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Clinical Outcome
12 results:
1. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
[TBL] [Abstract] [Full Text] [Related]
2. A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma.
Wu S; Li X
Bioengineered; 2021 Dec; 12(1):1642-1662. PubMed ID: 33955826
[TBL] [Abstract] [Full Text] [Related]
3. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
[TBL] [Abstract] [Full Text] [Related]
4. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract] [Full Text] [Related]
5. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
[TBL] [Abstract] [Full Text] [Related]
6. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract] [Full Text] [Related]
7. SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors.
Panwalkar P; Pratt D; Chung C; Dang D; Le P; Martinez D; Bayliss JM; Smith KS; Adam M; Potter S; Northcott PA; Mascarenhas L; Shows J; Pawel B; Margol A; Huang A; Judkins AR; Venneti S
Neuro Oncol; 2020 Jun; 22(6):785-796. PubMed ID: 31912158
[TBL] [Abstract] [Full Text] [Related]
8. Immune infiltration in renal cell carcinoma.
Zhang S; Zhang E; Long J; Hu Z; Peng J; Liu L; Tang F; Li L; Ouyang Y; Zeng Z
Cancer Sci; 2019 May; 110(5):1564-1572. PubMed ID: 30861269
[TBL] [Abstract] [Full Text] [Related]
9. A Genetic Polymorphism in
Liu X; Swen JJ; Diekstra MHM; Boven E; Castellano D; Gelderblom H; Mathijssen RHJ; Vermeulen SH; Oosterwijk E; Junker K; Roessler M; Alexiusdottir K; Sverrisdottir A; Radu MT; Ambert V; Eisen T; Warren A; Rodríguez-Antona C; García-Donas J; Böhringer S; Koudijs KKM; Kiemeney LALM; Rini BI; Guchelaar HJ
Clin Cancer Res; 2018 May; 24(10):2350-2356. PubMed ID: 29490989
[No Abstract] [Full Text] [Related]
10. Cutaneous presentation of post-renal transplant lymphoproliferative disorder: a series of four cases.
Salama S; Todd S; Cina DP; Margetts P
J Cutan Pathol; 2010 Jun; 37(6):641-53. PubMed ID: 19903218
[TBL] [Abstract] [Full Text] [Related]
11. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
[TBL] [Abstract] [Full Text] [Related]
12. E-cadherin expression in upper-urinary-tract carcinoma.
Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
Int J Cancer; 1997 Aug; 74(4):446-9. PubMed ID: 9291437
[TBL] [Abstract] [Full Text] [Related]
